Abstract:Metabolic reprogramming is a hallmark of malignant transformation, and loss of isozyme diversity (LID) contributes to this process. Isozymes are distinct proteins that catalyze the same enzymatic reaction but can have different kinetic characteristics, subcellular localization, and tissue specificity. Cancer-dominant isozymes that catalyze rate-limiting reactions in critical metabolic processes represent potential therapeutic targets. Here, we examined the isozyme expression patterns of 1,319 enzymatic reactions in 14 cancer types and their matching normal tissues using The Cancer Genome Atlas mRNA expression data to identify isozymes that become cancer-dominant. Of the reactions analyzed, 357 demonstrated LID in at least one cancer type. Assessment of the expression patterns in over 600 cell lines in the Cancer Cell Line Encyclopedia showed that these reactions reflect cellular changes instead of differences in tissue composition; 50% of the LID-affected isozymes showed cancer-dominant expression in the corresponding cell lines. The functional importance of the cancer-dominant isozymes was assessed in genome-wide CRISPR and RNAi loss-of-function screens: 17% were critical for cell proliferation, indicating their potential as therapeutic targets. Lists of prioritized novel metabolic targets were developed for 14 cancer types; the most broadly shared and functionally validated target was acetyl-CoA carboxylase 1 (ACC1). Small molecule inhibition of ACC reduced breast cancer viability in vitro and suppressed tumor growth in cell line- and patient-derived xenografts in vivo. Evaluation of the effects of drug treatment revealed significant metabolic and transcriptional perturbations. Overall, this systematic analysis of isozyme expression patterns elucidates an important aspect of cancer metabolic plasticity and reveals putative metabolic vulnerabilities. Significance: This study exploits the loss of metabolic isozyme diversity common in cancer and reveals a rich pool of potential therapeutic targets that will allow the repurposing of existing inhibitors for anticancer therapy. See related commentary by Kehinde and Parker, p. 1695.

Mitochondrial ETF insufficiency drives neoplastic growth by selectively optimizing cancer bioenergetics

ATG12 Deficiency Leads to Tumor Cell Oncosis Owing to Diminished Mitochondrial Biogenesis and Reduced Cellular Bioenergetics

Manipulating mitochondrial electron flow enhances tumor immunogenicity

Electron transport chain inhibition increases cellular dependence on purine transport and salvage

Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8 + T cell metabolic fitness and function in tumors

Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

Mitochondrial fitness and cancer risk

A Mitochondrial EglN1-AMPKa Axis Drives Breast Cancer Progression by Enhancing Metabolic Adaptation to Hypoxic Stress

Dysregulated metabolism contributes to oncogenesis

Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion

Neutrophil Extracellular Traps Drive Mitochondrial Homeostasis in Tumors to Augment Growth

Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis

Vesicle-mediated mitochondrial clearance underlies an actionable metabolic vulnerability in triple-negative breast cancer

The cytokine Meteorin-like inhibits anti-tumor CD8+ T cell responses by disrupting mitochondrial function

Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion

The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis

An Overview: The Diversified Role of Mitochondria in Cancer Metabolism

Comprehensive Analysis of Metabolic Isozyme Targets in Cancer